长华集团：收到国内碳陶刹车盘客户产品购销合同 7月28日晚，长华集团（605018）发布公告称，公司近期收到国内碳陶刹车盘客户的产品购销合同，产 品终端应用于国内某知名飞行汽车公司，产品主要为碳陶盘关键金属结构件。此次项目生命周期5年， 预计生命周期总销售金额超1亿元，此次项目预计在2026年第二季度逐步开始量产。 资料显示，长华集团成立于1993年11月，主营业务是汽车金属零部件的研发、生产、销售。 所属行业：汽车–汽车零部件–其他汽车零部件 中科环保：上半年净利润1.96亿元 同比增长19.83% 7月28日晚，中科环保（301175）公布了2025年半年度业绩快报，公司上半年度实现营业收入8.48亿 元，同比增长4.48%；实现归属于上市公司股东的净利润1.96亿元，同比增长19.83%；基本每股收益为 0.13元/股。 所属行业：医药生物–医疗服务–医疗研发外包 苏交科：上半年净利润同比下降39.54% 拟10派0.2元 7月28日晚，苏交科（300284）公布了2025年半年报告，公司上半年度实现营业收入为17.76亿元，同比 下降13.75%；实现归属于上市公司股东的净利润9539.48万元，同比 ...

福安药业（300194）公告，全资子公司只楚药业近日收到国家药品监督管理局签发的药品注册证书。药 品名称为注射用丁二磺酸腺苷蛋氨酸，规格为0.5g，批准文号为国药准字H20254936。该药品适用于肝 硬化前和肝硬化所致肝内胆汁淤积，以及妊娠期肝内胆汁淤积。上述药品注册证书的获得将进一步丰富 子公司产品线，提升其市场竞争力。但受医药政策、市场环境变化等因素影响，上述产品的生产、销售 情况以及对公司业绩的具体影响存在不确定性。 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-024 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团烟台只楚药业有限公司（以下简称"只楚药业"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 注射用丁二磺 酸腺苷蛋氨酸 | 化药 4 类 | 0.5g | 只楚药业 | 国药准字 H20254936 | 经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。 | | --- | --- | --- | --- | --- | --- | | 药品名称 | 注册分类 | 规格 | 药品上市许 可持有人 | 批准文号 | 审批结论 | 注射用丁二磺酸腺苷蛋氨酸适用于肝硬化前和肝硬化所致肝内胆汁淤积；适 用于妊娠期肝内胆汁淤积。根据国家药品监督管理局数据查询信息平台显示，截 止目前，该药品已有 10 家企业（含只楚药业）通过一致性评价或视同通过一致 性评价。 上述药品注 ...

近期，福安药业（300194.SZ）发布2025年上半年业绩预告，公司预计2025年上半年净利润为1亿元至 1.3亿元，同比下降39.95%—53.81%。扣非净利润预计为9100万元—1.21亿元，同比下降40.50%— 55.25%。 这一成绩单与2024年上半年形成鲜明对比——当时公司净利润还保持着20.69%的增长，短短一年间， 其净利润从高速增长变成了近乎腰斩的业绩滑坡。 针对此次净利润下滑的具体原因和后续提振措施，《中国经营报》记者日前向福安药业方面致函并致电 采访，其证券部工作人员表示，会提醒董秘进行查看，但截至记者发稿暂未收到公司方面回应。 业绩"变脸" 中经记者苏浩卢志坤北京报道 （福安药业业绩预告公司公告/图） 年报显示，福安药业成立于2004年2月，主要从事化学药品的研发、生产、销售。其拥有药品研发、医 药中间体、原料药、制剂生产和销售的完整产业链布局，产品涉及抗生素类、抗肿瘤类、特色专科药类 等多个类别药品。 实际上，福安药业的业绩下滑趋势在年初已有征兆。 2025年第一季度报告显示，福安药业营业总收入4.68亿元，同比下降42.22%；归母净利润6904.9万元， 同比下降43.63 ...

福安药业：子公司收到硫辛酸片药品注册证书 智通财经7月21日电，福安药业(300194.SZ)公告称，公司全资子公司福安药业集团烟台只楚药业有限公 司近日收到国家药品监督管理局签发的药品注册证书，药品名称为硫辛酸片，注册分类为化学药品3 类，规格为0.2g和0.6g。硫辛酸片的适应症为用于糖尿病周围神经病变引起的感觉异常。该药品已有4家 企业（含只楚制药）通过一致性评价或视同通过一致性评价。 ...

上述药品注册证书的获得将进一步丰富子公司产品线，提升其市场竞争力。 但上述产品受国家政策、市场环境变化等因素影响，产品的生产、销售情况以及 对公司业绩的具体影响存在不确定性。请广大投资者审慎决策，注意投资风险。 证券代码：300194 证券简称：福安药业 公告编号：2025-023 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团烟台只楚药业有限公司（以下简称"只楚制药"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 药品名称 | 注册分类 | | 规格 | 药品上市许 可持有人 | 批准文号 | | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 化学药品 3 | 类 | 0.2g | 只楚制药 | 国 药 H20254844 | 准 字 | 经审查，本品符合药品注册 的有关要求，批准注册，发 | | 硫辛酸片 | ...

Policy Developments - The National Medical Products Administration (NMPA) reported five cases of illegal online sales of medical devices, including companies selling products without proper licenses and failing to meet regulatory requirements [2] Drug and Device Approvals - East China Pharmaceutical's subsidiary received approval for clinical trials of HDM2012, a novel antibody-drug conjugate targeting mucin-17, marking it as a global first-class biological product [3] - Novo Nordisk announced that the NMPA approved the new indication for Ozempic (semaglutide injection) for chronic kidney disease, making it the first GLP-1 receptor agonist approved for this use in China [4] - Wanfu Bio received a medical device registration certificate for its MSI detection kit, which is significant for various solid tumor patients [5] Financial Reports - Fuan Pharmaceutical projected a net profit decline of 39.95% to 53.81% for the first half of 2025, primarily due to price reductions from national procurement policies [6] Capital Market Activities - Kanghua Bio announced a transfer of shares that will change its controlling shareholder to Wanke Xin Bio, with a total transfer price of approximately 1.85 billion yuan [8] - Jichuan Pharmaceutical's stock will resume trading after a tender offer by Cao Fei, who will control 56.07% of the company post-offer [9] Industry Developments - A new oral antiviral drug for influenza, Marselevosavir, developed by Zhengxiang Pharmaceutical, has been approved for use in treating uncomplicated influenza in previously healthy adults [10] Public Opinion Alerts - Notai Bio is facing other risk warnings due to a prior administrative penalty for false reporting, which included inflating revenue and profits [11]

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

证券代码：300194 证券简称：福安药业 公告编号：2025-022 福安药业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、本期业绩预计情况 项 目 本报告期 上年同期 盈利：10,000 万元–13,000 万元 归属于上市公司股 盈利：21,647.75 万元 东的净利润 本次业绩预告相关财务数据未经注册会计师审计，敬请投资者注意投资风险。 三、业绩变动原因说明 （一）业绩变动情况 - 53.81%。公司业绩下降的主要原因是：随着集采在全国推行，公司主要产品销售价格大 幅度下降，营业收入降低，利润空间承压。 比上年同期下降：39.95% - 53.81% 盈利： 9,100 万元–12,100 万元 扣除非经常性损益 盈利：20,337.34 万元 后的净利润 比上年同期下降：40.50% -55.25% 二、与会计师事务所沟通情况 公司董事会关于2025年半年度业绩预告的情况说明。 特此公告。 福安药业（集团）股份有限公司 董事会 二〇二五年七月十八日 （二）非经常性损益对净利润的影响说明 本报告期，公司预计非经常性损益 ...

福安药业（300194）公告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为1亿元– 1.3亿元，同比下降39.95%-53.81%。扣除非经常性损益后的净利润预计为9100万元–1.21亿元，同比下降 40.50%–55.25%。业绩下降主要原因是随着集采在全国推行，公司主要产品销售价格大幅度下降，营业 收入降低，利润空间承压。 ...